ArticleOphthalmology science2026
Phenotyping of Patients with Age-Related Macular Degeneration Using Artificial Intelligence-Driven Biomarker Patterns in OCT.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optical Coherence Tomography Biomarkers Predicting Progression to Atrophy in Non-Exudative Age-Related Macular Degeneration.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To leverage artificial intelligence-based OCT analysis to classify age-related macular degeneration (AMD) images into distinct subgroups based on retinal layer and fluid biomarkers. Design: Retrospective analysis of a data set of retinal OCT images. Participants: Anonymized data from 157 patients with AMD and 58 healthy volunteers. Methods: This study analyzed OCT scans from patients with AMD and healthy volunteers to extract retinal layer thickness and fluid biomarkers by artificial intelligence-driven image segmentation. We performed dimensionality reduction using parametric Uniform Manifold Approximation and Projection, followed by k-means clustering to partition the continuous disease space into 9 subphenotypes for analysis. Statistical analyses included linear mixed-effects modeling, analysis of variance, and Fisher exact tests to assess biomarker differences, visual acuity (VA), and lesion size across clusters. We mapped International Classification of Diseases, 10th Revision (ICD-10) codes to validate disease staging. Main Outcome Measures: We examined the potential of artificial intelligence-driven biomarker patterns based on the comparison to traditional clinical measures such as VA, lesion size, and ICD-10 codes for different disease stages. Results: By dividing the continuous landscape into 9 regions for interpretability, we observed that each cluster was characterized by a distinct biomarker pattern. Clusters exhibited outer retinal thinning of varying degrees and showed significant differences in inner retinal layers, choroidal thickness, subretinal pigment epithelium material, and fluid presence compared with a healthy cohort, suggesting diverse AMD subtypes beyond simple characterization by VA and atrophic lesion size alone. The distribution of ICD-10 codes further supported the interpretation of the AMD landscape as a representation of AMD progression. Conclusions: This study reveals a continuous AMD landscape based on OCT-derived biomarkers, suggesting the existence of subphenotypes beyond traditional staging methods. The findings further highlight the limitations of fundus-based disease classification and support the role of OCT scans in personalized disease management. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.